Trump’s Trade Plans in Disarray Amid Appeal Over ‘Liberation Day’ Tariff Ruling
Former President Donald Trump’s trade agenda has hit a major roadblock after a federal court ruled his sweeping “Liberation Day” tariffs unlawful. The tariffs, introduced in April 2025, included a 10% blanket levy on all imports and higher, targeted tariffs on goods from over 60 countries. Trump framed the move as a bold step toward economic independence, claiming it would revitalize American manufacturing and reduce trade deficits.
However, the U.S. Court of International Trade found the action exceeded presidential authority, sparking legal and political chaos. The ruling has been temporarily paused as an appeal moves forward, but uncertainty now clouds the future of the tariffs and Trump’s broader trade strategy.
The decision has rattled markets and led to growing concern among business leaders and international trade partners. Economists warn that the continued legal fight could undermine investor confidence and strain global supply chains already under pressure from ongoing geopolitical tensions.
As the appeal proceeds, critics argue the case may redefine the limits of presidential power over trade policy. Supporters of the tariffs say they are necessary to protect U.S. jobs and industries. The outcome will be closely watched, with significant implications for America’s economic direction heading into 2026.
Pacific Airshow Gold Coast Cancelled as High Swells Dash Hopes of Beach Recovery from Erosion
The Pacific Airshow Gold Coast 2025 has been officially cancelled due to severe beach erosion caused by ex-Tropical Cyclone Alfred. The cyclone removed an estimated four million cubic metres of sand from the beaches, leaving the Surfers Paradise foreshore—where the event was scheduled—unsafe for the anticipated 200,000 attendees.
Despite extensive sand replenishment efforts by the City of Gold Coast, recurring king tides and large swells have significantly hindered recovery. Airshow director Kevin Elliott expressed deep disappointment but emphasized that the decision was necessary to prioritize long-term beach restoration and spectator safety. Attempts to reschedule or relocate the event proved unfeasible without compromising safety and show quality.
)
Ticket holders will receive full refund options. The event saw record pre-sale ticket numbers and is confirmed to return from August 14 to 16 in 2026. Gold Coast Mayor Tom Tate and Experience Gold Coast CEO John Warn expressed support for the decision and confidence in the event’s future success, reaffirming their commitment to making it one of Australia’s top family-oriented gatherings.
The cancellation marks a significant setback for the region’s tourism sector, which had anticipated a $33 million economic boost from the event. However, local officials remain optimistic about the event’s return in 2026.
PolyActiva Secures $40 Million to Revolutionize Glaucoma Treatment
Australian biotech company PolyActiva has raised $40 million in a major funding round as it advances its groundbreaking solution for treating glaucoma-related vision loss. The Melbourne-based firm is developing PA5108, a biodegradable ocular implant designed to replace the need for daily eye drops—an ongoing challenge in glaucoma treatment due to poor patient adherence.
The implant, which is inserted into the eye and gradually dissolves while releasing medication over a sustained period, offers an innovative alternative to current treatments. Many glaucoma patients struggle to consistently apply medicated drops, which are critical in reducing intraocular pressure and preventing long-term damage to the optic nerve. By removing the need for daily compliance, PA5108 could significantly reduce the risk of vision loss among millions affected by the condition.
With this funding, PolyActiva plans to begin a Phase 2b clinical trial in the United States in early 2025, building on promising Phase 2a results that showed a sustained pressure reduction of over 20% for six months. Most trial participants did not need supplemental eye drop therapy during the treatment period.
Chief Executive Vanessa Waddell described the implant as a “paradigm shift” in glaucoma care and expressed hopes that the company could become a household name in eye health—much like Cochlear in the hearing sector. She emphasized the potential global impact of improving patient outcomes with a low-maintenance, effective treatment method.
The $40 million injection will fund further clinical development, manufacturing scale-up, and regulatory preparation. With its strong scientific foundation and growing investor backing, PolyActiva is positioning itself as a leader in ocular drug delivery. If successful, its technology could redefine how glaucoma is managed, not just in Australia, but around the world.
RSM Australia Expands Insolvency Practice with Brooke Bird Acquisition
RSM Australia has announced the acquisition of Melbourne-based insolvency firm Brooke Bird, enhancing its restructuring and recovery capabilities. This strategic move aligns with RSM’s commitment to providing comprehensive support to businesses navigating financial challenges.
Brooke Bird, led by renowned experts Robyn Erskine AM and Adrian Hunter, specializes in corporate and personal insolvency, as well as business rescue and health diagnostics. Their client-centric approach and reputation for delivering clear, outcome-driven solutions will complement RSM’s existing services.
The integration of Brooke Bird into RSM’s operations is expected to strengthen the firm’s capabilities in managing complex insolvency cases and expand its reach across Victoria and beyond. Clients will benefit from an enhanced team of professionals dedicated to navigating financial distress and facilitating effective recovery strategies.
This acquisition underscores RSM Australia’s strategic focus on growth through targeted partnerships and investments in specialized expertise, reinforcing its position as a leading provider of professional services in the Australian market.
The combined entity is poised to offer a broader range of services to clients, ensuring robust support during challenging financial times and contributing to the overall stability and resilience of the business community.
Wable Targets Global Expansion to Support Neurodivergent Community
Wable, an innovative app designed specifically for neurodivergent individuals, is preparing to expand internationally after gaining strong traction in Australia. The platform, launched in early 2024, aims to create a safe and supportive space where people with autism, ADHD, and other neurodiverse conditions can build meaningful connections — whether for friendship, dating, or professional opportunities.
Co-founded by Holly Fowler, Wable stands out for its thoughtful design that caters to the unique social and sensory needs of its users. The app offers customizable color schemes to reduce sensory overload, a chat wheel feature that helps users start conversations, and a wellness toolbox filled with resources developed alongside mental health professionals. These features help reduce the stress and anxiety that often accompany social interactions for neurodivergent people.
After a successful launch in Australia, Wable expanded into New Zealand and is now planning to enter key global markets, including the United States, United Kingdom, and Canada. To support this growth, the company intends to raise $1.5 million in capital to further develop its technology and expand its reach.
The app is rapidly building a loyal user base attracted to its inclusive and understanding approach. By offering a platform tailored to the specific challenges faced by neurodivergent individuals, Wable is carving out a unique space in the social networking and job market landscape.
With the upcoming global rollout, Wable aims to become a leading platform where neurodivergent people worldwide can find community and opportunities without judgment or barriers. The company’s vision is to foster acceptance and connection on a global scale, helping millions navigate social and professional spaces with confidence and support.
